File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.coviro.2012.06.005
- Scopus: eid_2-s2.0-84865113216
- PMID: 22795202
- WOS: WOS:000312112900016
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Vaccine prospect of Kaposi sarcoma-associated herpesvirus
Title | Vaccine prospect of Kaposi sarcoma-associated herpesvirus |
---|---|
Authors | |
Issue Date | 2012 |
Citation | Current Opinion in Virology, 2012, v. 2, n. 4, p. 482-488 How to Cite? |
Abstract | Infection of Kaposi sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8) is estimated to account for 34,000 new cancer cases globally. Unlike other herpesviruses, KSHV is not ubiquitous but is highly prevalent in some areas, such as sub-Saharan Africa where Kaposi sarcoma is the leading cancer among adults. While latent infection of KSHV plays a major and direct role in tumorigenesis, viral lytic replication also makes significant contributions to this process. Efforts to develop a KSHV vaccine are limited, but studies with EBV have provided important lessons. Informative vaccine research has been conducted in the mouse infection model of a closely related rodent virus, murine gammaherpesvirus-68 (MHV-68 or γHV-68). This mouse model has generated fundamental principles for an effective vaccination strategy. KSHV vaccines designed to prevent a naïve host from infection and to boost the immune control of KSHV in persistently infected people will have major impact on individuals who are at a high risk of developing KSHV-associated diseases. |
Persistent Identifier | http://hdl.handle.net/10722/285699 |
ISSN | 2023 Impact Factor: 5.7 2023 SCImago Journal Rankings: 1.833 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wu, Ting Ting | - |
dc.contributor.author | Qian, Jing | - |
dc.contributor.author | Ang, Jian | - |
dc.contributor.author | Sun, Ren | - |
dc.date.accessioned | 2020-08-18T04:56:25Z | - |
dc.date.available | 2020-08-18T04:56:25Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | Current Opinion in Virology, 2012, v. 2, n. 4, p. 482-488 | - |
dc.identifier.issn | 1879-6257 | - |
dc.identifier.uri | http://hdl.handle.net/10722/285699 | - |
dc.description.abstract | Infection of Kaposi sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8) is estimated to account for 34,000 new cancer cases globally. Unlike other herpesviruses, KSHV is not ubiquitous but is highly prevalent in some areas, such as sub-Saharan Africa where Kaposi sarcoma is the leading cancer among adults. While latent infection of KSHV plays a major and direct role in tumorigenesis, viral lytic replication also makes significant contributions to this process. Efforts to develop a KSHV vaccine are limited, but studies with EBV have provided important lessons. Informative vaccine research has been conducted in the mouse infection model of a closely related rodent virus, murine gammaherpesvirus-68 (MHV-68 or γHV-68). This mouse model has generated fundamental principles for an effective vaccination strategy. KSHV vaccines designed to prevent a naïve host from infection and to boost the immune control of KSHV in persistently infected people will have major impact on individuals who are at a high risk of developing KSHV-associated diseases. | - |
dc.language | eng | - |
dc.relation.ispartof | Current Opinion in Virology | - |
dc.title | Vaccine prospect of Kaposi sarcoma-associated herpesvirus | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.coviro.2012.06.005 | - |
dc.identifier.pmid | 22795202 | - |
dc.identifier.scopus | eid_2-s2.0-84865113216 | - |
dc.identifier.volume | 2 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 482 | - |
dc.identifier.epage | 488 | - |
dc.identifier.eissn | 1879-6265 | - |
dc.identifier.isi | WOS:000312112900016 | - |
dc.identifier.issnl | 1879-6257 | - |